All News
New Oral Option for axSpA: Filgotinib for Radiographic and Non-Radiographic Disease
The Janus kinase inhibitor (JAKi) class has been increasingly used in the management of axial spondyloarthritis (axSpA) over the past five years, offering effective oral alternatives to injectable biologics. But are all JAK inhibitors the same?
Read Article
Day 4 EULAR Report
The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented.
Read Article
New: Classification Critiera and Recommendations in SpA
2026 EULAR Press Release
ASAS and the SPARTAN have updated their key classification criteria for axial SpA (axSpA). EULAR has also recently revised their recommendations on the role of imaging in the diagnosis and clinical management of spondyloarthritis (SpA). Both were presented at the EULAR 2026 annual Congress in London.
Read Article
Strike First: TNFi vs. Step-Up Therapy in Early Peripheral SpA
The approach to the treatment of peripheral SpA has been the same for a long time. The guidelines recommend starting with NSAIDs, escalate to conventional synthetic DMARDs, typically sulfasalazine or methotrexate and reserve biologics for patients who fail those. According to a new phase 3 trial presented at EULAR 2026, there may be a different way to approach this.
Read Article
Improving Referrals for Inflammatory Arthritis
Dr. Antoni Chan discusses abstracts POS1284 and POS0784 presented at EULAR 2026 in London
https://t.co/p1iT8yPNzF https://t.co/gEyuEwW4aj
Dr. John Cush RheumNow ( View Tweet)
Strike First: TNFi vs. Step-Up Therapy in Early Peripheral SpA
The approach to treating peripheral SpA has remained the same for a long time. The guidelines recommend starting with NSAIDs, escalating to conventional synthetic DMARDs, typically sulfasalazine or methotrexate, and https://t.co/iEqzp6FStv
Dr. John Cush RheumNow ( View Tweet)
The pain that inflammation does not explain in SpA and PsA
At EULAR 2026, the NEUPIA study (OP0317), a prospective observational investigation conducted at KU Leuven and University Hospitals Leuven, provides the most detailed longitudinal characterisation to date of these https://t.co/OYMf4KKBc1
Dr. John Cush RheumNow ( View Tweet)
🏠 Take Home Messages from the early #axSpA session
🔺 Earlier diagnosis is possible and better
🔺 Early axSpA is not synonymous to mild
🔺 Longitudinally, early axSpA is heterogeneous
🔺 MRI has transformed the field
❗️Beware of pitfalls
#EULAR2026 @RheumNow https://t.co/IhGQSxssyd
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Patient-initiated telemedicine follow-up cut rheumatology visits by 25% in stable #SpA, but not equally for everyone. Reductions were greatest in men, axSpA, bDMARD users, and the oldest patients (64+, 34% fewer visits). Patient-centered care delivery @RheumNow #EULAR2026 POS1345
Jiha Lee JihaRheum ( View Tweet)
SELECT-Axis 2 trial and Withdrawal of Upadacitinib - Of 734 pts, 194 were in remission at wk104--> UPA w/d & 22% maintained drug-free remission for >48wks. Rest flared, median time to flare: 3.1 mos (89% regained LDA by wk24 w/ restart) #EULAR2026 #axSpA POS1350 https://t.co/7A7CAHxLxX
Dr. John Cush RheumNow ( View Tweet)
Risk of Parkinsons? RA patients have 28% lower Parkinson's risk vs general population (HR 0.72); axSpA had HIGHER risk (HR 1.29). Non-TNF biologics in RA reduced PD risk further (HR 0.74). No effect seen in PsA/axSpA. #EULAR2026 Abstr #POS1116 https://t.co/1vZoZGEu5Z
Dr. John Cush RheumNow ( View Tweet)
🏠 Take Home Messages from the early #axSpA session
🔺 Earlier diagnosis is possible and better
🔺 Early axSpA is not synonymous to mild
🔺 Longitudinally, early axSpA is heterogeneous
🔺 MRI has transformed the field
❗️Beware of pitfalls
#EULAR2026 @RheumNow
Nelly ZIADE 🍀 Nellziade ( View Tweet)
A high proportion of juvenile-onset SpA progress toward a r-axSpA phenotype
Results from the Spanish REGISPON-3
POS1352
#EULAR2026 @RheumNow https://t.co/XicguAdXJ1
Nelly ZIADE 🍀 Nellziade ( View Tweet)
How many patients with IBD have axSpA?
POS1338 #EULAR2026 @RheumNow
⬇️⬇️⬇️ https://t.co/29qkrCnDYz
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Is the risk of uveitis comparable between infliximab sc and adalimumab in patients with r-axSpA and prior AAU?
Yes! POS 1347
Multicenter randomised open-label trial
N=56
#EULAR2026 @RheumNow https://t.co/kP7ropPkpC
Nelly ZIADE 🍀 Nellziade ( View Tweet)
What happens after withdrawal of upadacitinib in patients with axSpA who achieved remission?
Data from 194 patients from the SELECT-AXIS2 RCT:
▶️ Remission maintained in 1/4 at48 weeks
POS1350 #EULAR2026 @RheumNow https://t.co/Z7nDwMuQux
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 LB0002 More great news for dual IL17A and -F blockade. An open label Phase II study of Sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody'-3 in #axSpA: clinical efficacy, improvement in PROM and imaging inflammation. Looking forward to the RCT phase @RheumNow https://t.co/Xtxa8fALzN
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#antisynthetase #EULAR/ACR #classification #criteria
#EULAR2026
@RheumNow
Based on >2k pts
Probable v definite
Ignore low + #synthetase #antibodies
Seems reasonable and applicable
➡️my opinion https://t.co/MyCRiCSiGo
Links:
Janet Pope Janetbirdope ( View Tweet)
LB0002: Sonelokimab (IL-17A/F Nanobody, ~40 kDa) in #axSpA Phase 2: 81% ASAS40 and 54% ASAS partial remission at 12 weeks. Mean ASDAS improvement of −2.0 from baseline. @RheumNow #EULAR2026 https://t.co/TjvtnFPCdj
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Even with tight T2T, ARCTIC 10yr follow-up (n=170) show 9% had RA-ILD on HRCT, plus another 19% with non-specific interstitial findings. Male sex and older age were risk factors. Seropositivity was not. Vigilance remains essential. @RheumNow #EULAR2026 POS1270
Jiha Lee JihaRheum ( View Tweet)
